ESTRO 2024 - Abstract Book

S2318

Clinical - Urology

ESTRO 2024

Conclusion:

This study demonstrates the dosimetric feasibility of ultra-hypofractionated radiation therapy using a 1.5T MRL for low-risk prostate cancer. Reduced PTV margins in MRL plans resulted in substantial reductions in rectal and bladder doses, providing an opportunity to increase radiation dose without compromising plan quality. However, VMAT plans outperformed MRL plans in terms of target volume dose homogeneity. This significant difference may give prostate cancer patients the option of increasing their radiation dose. Although this study supports the dosimetric feasibility of 1.5-T MRgRT, more research on different planning systems is needed as well as long-term follow-ups to determine the clinical effects.

Keywords: MR-linac, Prostate cancer, Radiotherapy

418

Poster Discussion

PSICHE trial (NCT05022914), a trial testing a PSMA guided approach for relapse after prostatectomy

Giulio Francolini 1 , Ilaria Bonaparte 2 , Vanessa Di Cataldo 1 , Pietro Garlatti 2 , Beatrice Detti 1 , Saverio Caini 3 , Mauro Loi 1 , Gabriele Simontacchi 1 , Isacco Desideri 2 , Daniela Greto 1 , Giulio Frosini 2 , Luca Burchini 2 , Luisa Caprara 2 , Luca Vaggelli 4 , Nicola Simoni 5 , Federico Colombo 5 , Niccolò Bertini 2 , Carolina Orsatti 2 , Ciro Franzese 6 , Marta Scorsetti 6 , Arturo Chiti 7 , Icro Meattini 2 , Richard K. Valicenti 8 , Lorenzo Livi 2